Drug news
CHMP recommends Alimta for continuation maintenance therapy in NSCLC
The European Committee for Medicinal Products for Human Use (CHMP) delivered a positive opinion for the use of Alimta (pemetrexed) from Eli Lilly as continuation maintenance therapy in patients with advanced NSCLC who have already received an initial treatment with the agent. This opinion will now be reviewed by the European Commission. The opinion was based on the results from the PARAMOUNT Phase III trial.The drug will be submitted to the FDA in 2012 for initial Alimta treatment followed by maintenance therapy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.